Barclays
PROK icon

Barclays’s ProKidney PROK Stock Holding History

Barclays’s Portfolio PROK Stock Details PROK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$262K Sell
146,284
-23,717
-14% -$50.3K ﹤0.01% 3540
2025
Q4 		$381K Buy
170,001
+170,000
+17,000,000% +$447K ﹤0.01% 4007
2025
Q3 		$2 Hold
1
– – ﹤0.01% 5438
2025
Q2 		$1 Sell
1
-119,038
-100% -$92.7K ﹤0.01% 5200
2025
Q1 		$104K Sell
119,039
-52,758
-31% -$73.2K ﹤0.01% 4392
2024
Q4 		$290K Buy
171,797
+25,476
+17% +$45.9K ﹤0.01% 4135
2024
Q3 		$281K Buy
146,321
+124,667
+576% +$283K ﹤0.01% 4127
2024
Q2 		$53.3K Sell
21,654
-9,943
-31% -$26.7K ﹤0.01% 4184
2024
Q1 		$51.8K Sell
31,597
-30,218
-49% -$44.4K ﹤0.01% 4608
2023
Q4 		$110K Buy
61,815
+48,234
+355% +$103K ﹤0.01% 4619
2023
Q3 		$62.2K Sell
13,581
-4,260
-24% -$40.8K ﹤0.01% 3778
2023
Q2 		$200K Buy
+17,841
New +$190K ﹤0.01% 3239

Other funds holding PROK

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
AGP
Artia Global Partners Miami, Florida $499M AUM 186.05% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Barclays's PROK Position: Q1 2026 in Review

Barclays reduced its ProKidney (PROK) stake by 14% in Q1 2026, selling an estimated $50.3K and leaving 146,284 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #3540.

Barclays first reported a position in PROK in Q2 2023 and has held it in 12 quarters since. The position peaked at $381K in Q4 2025. 71 funds tracked by Wall St. Rank hold PROK as of Q1 2026.

  • Barclays held 146,284 shares of ProKidney worth $262K as of Q1 2026.
  • Barclays sold 23,717 ProKidney shares in Q1 2026, an estimated $50.3K.
  • ProKidney made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3540 holding.
  • Barclays first reported a position in ProKidney in Q2 2023 and has held it in 12 quarters since.
  • Barclays's ProKidney position peaked at $381K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held ProKidney as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.